Aytu Biopharma, Inc (AYTU): R&D Expense
$0
Year ended 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $0 | -100.0% | 2026-09-22, From 2025-07-01 |
| 2025-06-30 | $1.33M | -52.1% | 2026-09-22, From 2024-07-01 |
| 2024-06-30 | $2.77M | -32.4% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $4.09M | -67.7% | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | $12.66M | n/c | 2023-10-12, From 2021-07-01 |
| 2021-06-30 | $5.62M | +226.5% | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | $1.72M | +192.3% | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $589.1K | +251.5% | 2020-10-06, From 2018-07-01 |
| 2018-06-30 | $167.6K | -82.5% | 2019-09-26, From 2017-07-01 |
| 2017-06-30 | $959.9K | -84.3% | 2018-09-06, From 2016-07-01 |
| 2016-06-30 | $6.13M | +90.3% | 2017-08-31, From 2015-07-01 |
| 2015-06-30 | $3.22M | -18.2% | 2016-09-01, From 2014-07-01 |
| 2014-06-30 | $3.93M | n/a | 2015-09-28, From 2013-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $339.54M | +12.7% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $197.10M | +54.4% |
Compare AYTU, NKTR, DERM, AGIO side by side · Screen every company in Pharmaceutical Preparations ↗